Navigation Links
Experimental Drug Fights Bone Marrow Cancers
Date:12/9/2008

There are currently no FDA-approved treatments for these malignancies

TUESDAY, Dec. 9 (HealthDay News) -- An experimental drug called CYT387 blocks an enzyme that causes bone marrow cancers called myeloproliferative disorders (MPDs), according to U.S. researchers who conducted tests in mice and human cells.

The findings were to be presented Tuesday at the annual meeting of the American Society of Hematology, in San Francisco.

The researchers, from Oregon Health & Science University's Knight Cancer Institute, found that CYT387 was "very effective" against a specific type of cancer cell driven by an enzyme mutation called JAK2-V617F. The drug binds to the V617F mutation in the JAK2 enzyme.

"In the mouse model, the drug blocked JAK2-V617F, normalized blood counts and reduced enlarged spleens back to a normal size. It is a very promising compound," researcher Dr. Thomas Bumm said in a university news release.

There are no U.S. Food and Drug Administration-approved targeted treatments for the "big three" MPDs -- polycythemia vera, essential thrombocythemia and primary myelofibrosis.

"Based on the efficacy we demonstrated in the mouse model, there is a good chance that CYT387 will enter clinical trials as early as 2009," principal investigator Dr. Michael Deininger, head of the hematological malignancies program, said in the news release.

The study was funded by Cytopia Research Pty Ltd. of Australia, which makes the drug.

More information

The Leukemia and Lymphoma Society has more about MPDs.



-- Robert Preidt



SOURCE: Oregon Health & Science University, news release, Dec. 9, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Page: 1

Related medicine news :

1. Experimental Vaginal Gel Doesnt Ward Off HIV
2. Experimental TB drug explodes bacteria from the inside out
3. Cephalon and ImmuPharma Sign a $15 million Option Agreement for Late- Stage Experimental Lupus Medication
4. Phase II Trial of Experimental Anti-Coagulant Reports Safety and Outcomes Data
5. Experimental Apartment in Beijing Achieves 99% Purity of Indoor Air
6. Experimental Drug Fights Multiple Sclerosis Activity
7. Experimental Therapy Beats Back One Patients Melanoma
8. Experimental agent blocks prostate cancer in animal study
9. Experimental Drug Eases Symptoms of Mild Alzheimers
10. Experimental Blood Substitutes Unsafe, Study Finds
11. Honda to Showcase Experimental Walking Assist Device
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Drug Fights Bone Marrow Cancers
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology: